Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo®

AI Briefing

• – Opdivo receives FDA approval for classical Hodgkin lymphoma treatment
• – Opdivo and chemotherapy combination approved for adult and pediatric patients
• – First immunotherapy combination for previously untreated, Stage III or IV cHL